WO2018134713A1

WO2018134713A1 - Hair growth retardant composition

Info

Publication number: WO2018134713A1
Application number: PCT/IB2018/050222
Authority: WO
Inventors: Rajan Raghavachari
Original assignee: R&R Salons Pvt. Ltd.
Priority date: 2017-01-21
Filing date: 2018-01-13
Publication date: 2018-07-26

Abstract

The present subject matter provides to a cosmetic composition. More specifically, the subject matter provides a hair growth retardant composition comprising dihydromyricetin as an inhibitor; at least one oxidation preventing agent wherein the oxidation preventing agent is selected from: an acidifying agent, an antioxidant, a chelator, and a combination thereof; and a cosmetically acceptable vehicle. The subject matter further provides, the composition comprising any one or more of Gymnema sylvestre and Narcissus tazetta bulb extract as inhibitors.

Description

"HAIR GROWTH RETARDANT

COMPOSITION"

TECHNICAL FIELD

[001] The subject matter relates to cosmetic compositions in general. More specifically, the subject matter relates to composition for retardation of hair growth.

BACKGROUND

[002] There are a number of hair related conditions that need care. Some of the conditions include Hypertrichosis and Hirsutism. Hypertrichosis is also knows as werewolf syndrome, in that hair grow randomly or different locations of the body. Hirsutism is a type of hypertrichosis exclusive to women and children, resulting from an excess of androgen-sensitive hair growth. In some other cases, even natural hairs become unwanted and removal or treatment of which is desirable.

[003] There is a need for reducing the growth of excessive unwanted body hair in terms of its length, thickness, density (number of hair in a given skin area) and /or delay the growth of unwanted hair on body.

[00 ] There are a number of solutions that attempt to provide treatment for the unwanted hair growth. Several methods such as depilation and epilation are used for the temporary removal of hairs. The permanent removal of hairs requires use of laser and hormones that are dangerous to the health. Some of the commercially available hair retardants have a number of problems. For example, the shelf life of some of these retardants is very short. That is, the retardants deteriorate and tend to lose its physical characteristics in a short span of time. In one possibility the hair retardants may lose its color and lose its aesthetic charm for a user. Therefore, there is a need to provide a composition that not only addresses the problem of discoloration of the cosmetic composition but also enhances cosmetic benefits.

SUMMARY

[005] The present subject matter provides solution to the above and other problems. The present subject matter provides a composition that helps to delay, reduce, and weaken the growth of unwanted body hair while optimizing shelf life of the composition. Available compositions for hair growth retardation often lose its aesthetics, therefore shelf life, due to its discoloration. Discoloration may be due to oxidation of ingredient of the composition. One such ingredient in the composition is Dihydromyricetin, oxidation of which causes discoloration of composition. Dihydromyricetin is one of the most desirable ingredients in a cosmetic composition because it has a number of advantages, however, use of Dihydromyricetin needs to be compromised with reduced shelf life of the composition. Therefore, there is a need to provide a composition that not only addresses the problem of discoloration but also enhances cosmetic benefits and shelf life of the composition. The present subject matter provides a composition comprising an inhibitor and an acidifying agent. In some embodiments, the inhibitor is dihydromyricetin and the acidifying agent is glycolic acid. It shall become clear to a person skilled in the art, that Dihydromyricetin is also traded as telocapil™ and used interchangeably throughout this specification.

[006] The present subject matter provides a cosmetic composition comprising at least one inhibitor; at least one oxidation preventing agent and cosmetically acceptable vehicle. The inhibitor inhibits tyrosine kinase activity of the IGF-i receptor or phosphodistearase activity. The inhibitor is selected from telocapil™(dihydromyricetin), pilisoft® LSs7 o(Gymnema sylvestre extract), dormin (Narcissus tazetta bulb extract)and a combination thereof. In one embodiment the inhibitor is telocapil™. I n another embodiment, the inhibitor is pilisoft® LS9760. I n another embodiment, the composition comprises telocapil™ and pilisoft® LS9760. The inhibitor is present in the composition in an amount of o.oi-2owt%. I n one embodiment the inhibitor is present in an amount of 0.1 - 5.owt%. In another embodiment, the inhibitor is present in an amount of o.2-3.owt%.The composition also comprises oxidation preventing agent. The oxidation preventing agent is selected from an acidifying agent, an antioxidant, a chelator and a combination thereof. In an embodiment, the oxidation preventing agent is acidifying agent. The acidifying agent is a hydrogen ion donor. In some embodiments, the acid ifying agent may be from a class of hydroxy or carboxylic acids. In one embodiment, the acidifying agent is glycolic acid. The acidifying agent is present in an amount of o.oi - 25 wt%. I n one embodiment, the acidifying agent is present in an amount of 0.1 - 10. o wt%. I n another embodiment, the acidifying agent is present in an amount 0.2 - 8 wt%. I n yet another embodiment the oxidation preventing agent is a sacrificial agent. The sacrificial agent is an antioxidant and is selected from sodium-bisulphite, butylated hydroxytoluene (BHT), ascorbic acid and its derivatives, tocopherol and its derivatives or a combination thereof. The antioxidant is present in an amount of o.oi - 2 wt%. In one embodiment, the sacrificial agent is present in an amount o.i-iwt%. In some embodiments, the oxidation preventing agent is a chelator. The chelator is selected from disodium ethylenediaminetetraacetate (EDTA), diethylenetriaminepentaacetic acid (DTPA), trisodiu m ethylenediaminedisuccinate (EDDS) or a combination thereof. In one embodiment the amount of chelator is o.oi - 2.owt%. In another embodiment, the amount of chelator is 0.1 - iwt%. In some of the embodiments the composition comprises Narcissus tazetta bulb extract (generally traded as dormin and used interchangeably throughout this specification) in an amount of o.oi - 2owt%. I n another embodiment, composition comprises papaya extract in an amount of 0.05 - 5.owt%. The composition comprises cosmetically acceptable agent/vehicle selected from preservatives, humectants, colourants and emulsifiers. The cosmetically acceptable agent/vehicle is present in an amount of from 40 to 99 wt%. The composition has a pH between 3.8 to 5.5. I n one embodiment the cosmetic composition comprising telocapil™ in an amount of o.oi - 25 wt%; pilisoft® LS9760 in an amount of o.oi - 25 wt%; glycolic acid in an amount of 0.01-20 wt%; and cosmetically acceptable vehicle. I n one embodiment the cosmetic composition comprising telocapil™ and dormin. I n another embodiment the cosmetic composition comprising pilisoft® LS9760 and dormin. I n yet another embodiment, the composition comprises telocapilTM, pilisoft® LS9760 and dormin.

[007] The present subject matter provides, a cosmetic composition comprising: dihydromyricetin as an inhibitor; at least one oxidation preventing agent wherein the oxidation preventing agent is selected from: an acidifying agent, an antioxidant, a chelator, and a combination thereof; and a cosmetically acceptable vehicle. In a first embodiment, the inhibitor includes any one or more of Cymnema sylvestre and Narcissus tazetta bulb extract. I n a second embodiment, the inhibitor is present in the composition in any one of amount range of: o.oi-2owt%, o.i-5.owt% and o.2-3wt%. In a third embodiment, the acidifying agent is glycolic acid. I n a fourth embodiment, the acidifying agent is present in the composition in any one of amount range of: 0.01-25 wt%, o.i-io.o wt%, and 0.2 wt% - 8 wt%. In a fourth embodiment, the antioxidant is selected from: sodium-bisulphite, butylated hydroxytoluene (BHT), ascorbic acid and its derivatives, tocopherol and its derivatives, and a combination thereof. In a fifth embodiment, the antioxidant is present in an amount of o.oi -2.0 wt%, preferably 0.1-1.0 wt%. In a sixth embodiment, the chelator is selected from: disodium ethylenediaminetetraacetate (EDTA), diethylenetriaminepentaacetic acid (DTPA), trisodium ethylenediaminedisuccinate (EDDS), and a combination thereof. In a seventh embodiment, the chelator is present in an amount of 0.01-2. owt%, preferably 0.1-1.0 wt%. In a eighth embodiment, the composition further comprises a polyol selected from 1,3-propane diol, propylene glycol, glycerol, sorbitol, and polyethylene glycol. In a ninth embodiment, the polyol is present in the composition in any one of range of: 0.1- 30 wt%, 0.2- 20 wt% and 0.5- 16 wt%. In a tenth embodiment, the composition has a pH in any one of the range of: 3.8-5.5, 4.0-5.5 and 4.0- 5.0.

[008] According to another aspect, the present subject matter provides a cosmetic composition comprising dihydromyricetin in an amount of o.oi-25wt %; Cymnema sylvestre in an amount of 0.01-25 wt%; glycolic acid in an amount of o.oi-2owt%; and cosmetically acceptable vehicle.

[009] According to yet another aspect, the subject matter provides a cosmetic composition comprising: a combination of Cymnema sylvestre and Narcissus tazetta bulb extract as inhibitor and a cosmetically acceptable vehicle.

BRIEF DESCRIPTION OF DRAWINGS

[0010] The subject matter is now described with reference to the accompanying figures, in that:

[0011] FIG. 1 shows comparative graphical representation antifproliferative effects of a number of compositions, including the compositions of the present of the present subject matter; and

[0012] FIG. 2 and FIG. 3 show results of discoloration and stability study of a number of compositions, including the compositions of the present of the present subject matter. DETAILED DESCRIPTION

[0013] Before the present subject matter is described in further detail, it is to be understood that the subject matter is not limited to the particular embodiments described, and may vary as such. It is also to be understood that the terminology used throughout the preceding and forthcoming discussion is for the purpose of describing particular embodiments only, and is not intended to be limiting. It must be noted that as used herein, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. In the following discussions units are in wt/wt

[001 ] Hypertrichosis is also called Ambras syndrome. Hypertrichosis is a condition that causes an abnormal amount of hair growth over the body. An aggravated form of hypertrichosis is commonly known as werewolf syndrome, because it causes appearance of a patientsimilar to that of a mythical werewolf. Hypertrichosis is classified in two types, generalized hypertrichosis and localized hypertrichosis. The classification is based on the effects of hypertrichosis on a patient. For example, generalized hypertrichosis affect over the entire body of the patient, whereas, localized hypertrichosis, affects a restricted area on the body of the patient. Each of the generalized hypertrichosis and localized hypertrichosis can be either congenital (present at birth) or acquired later in life.

[0015] Congenital generalized hypertrichosis is not usually observed. Congenital generalized hypertrichosis may cause asymmetrical hair distribution, however palms, soles, and mucous membranes may not get affected. Acquired generalized hypertrichosis may be caused conditions like cancer causing hair growth known as malignant down. In some cases, oral and topical minoxidil treatments are also known to cause acquired generalized hypertrichosis.

[0016] Congenital localized hypertrichosis is an increase in hair density/length etc and similar to congenital generalized hyepertrichosis, congenital localized hypertrichosis is also not usually observed. Acquired localized hypertrichosis is an increase in hair density length and is often secondary to irritation or trauma. In some cases, Minoxidil, a medicine for preventing hair loss, is thought to trigger acquired localized hypertrichosis. Medication-induced hair changes are often reversible.

[0017] Hypertrichosis is diagnosed clinically via the occurrence of hair in excess of what is expected for age, sex, and ethnicity in areas that are not androgen-sensitive. The excess can be in the form of excessive length or density and may consist of any hair type (lanugo, vellus, or terminal).

[0018] Hirsutism is a type of hypertrichosis exclusive to women and children, resulting from an excess of androgen-sensitive hair growth. Patients with hirsutism exhibit patterns of adult male hair growth. Chest and back hair are often present on women with hirsutism.

[0019] Hirsutism may be congenital or acquired. It is linked to excessive male hormones in women, thus symptoms may include acne, deepening of the voice, irregular menstrual periods, and the formation of a more masculine body shape. Increases in androgen (male hormone) levels are the primary cause of most hirsutism cases. If caused by increased levels of androgens, it can be treated with medications that reduce androgen levels. Some birth control pills and spironolactone reduce androgen levels.

[0020] The treatment for hypertrichosis or hirsutism is based on attempting to address the underlying cause. Acquired forms of hypertrichosis have a variety of sources, and are usually treated by removing the factor causing hypertrichosis, e.g. a medication with undesired side-effects. All hypertrichosis, congenital or acquired, can be reduced through hair removal. Hair removal treatments are categorized into two principal subdivisions: temporary removal and permanent removal. Treatment may have adverse effects by causing scarring, dermatitis, or hypersensitivity.

[0021] Temporary hair removal may last from several hours to several weeks, depending on the method used. These procedures are purely cosmetic. Depilation methods, such as trimming, shaving, and depilatories, remove hair to the level of the skin and produce results that last several hours to several days. Epilation methods, such as plucking, electrolysis, waxing, sugaring, threading remove the entire hair from the root, the results lasting several days to weeks. [0022] Permanent hair removal uses chemicals, energy of various types, or a combination to target the cells that cause hair growth, for example Laser based hair removal techniques. Some medication based solutions to reduce production of hair is currently under testing. One medicinal option suppresses testosterone by increasing the sex hormone-binding globulin. Another controls the overproduction of hair through the regulation of a luteinizing hormone.

[0023] However, the above techniques have respective limitations. For example, the laser based removal techniques fail to address issues relating white hair, or hormone based medication may have side effects on health. [002 ] The present subject matter provides a composition that does not have above and other limitations. The present subject matter provides a solution that helps in delaying, reducing, and weakening of the growth of unwanted body hair. The composition comprises at least one inhibitor and an oxidation preventing agent. The inhibitor(s) and the oxidation preventing agent may be provided with a cosmetically acceptable vehicle. In some embodiments the composition comprises more than one inhibitor. The inhibitor within the meaning of present subject matter includes the substances/materials that reduces, delays or weakens growth of body and facial hair. In one example such inhibitor may inhibit tyrosine kinase activities of the IGF-i Receptor that prevents the action of stimuli that normally promotes anagen follicular growth, thus resulting in reduced amount and impairs quality of body hair. Some examples of the inhibitor may include dihydromyricetin and nordihydroguaiaretic acid. Some other examples of the inhibitors may inhibit the hair grow retardation in a different manner than what is described above, however may still have the similar problem of discoloration as dihydromyricetin. It shall become clear to a person skilled in the art, after reading this specification, which the inhibitors or ingredients of hair growth retardation composition are also taught by this specification. For example, some inhibitors may attempt the hair grow retardation: by inhibiting phosphodiesterase activity, by inducing follicles into catagen phase, by blocking hair growth enzymes, or by slowing down mitosis rate of keratinocytes. In some examples, Inhibitors may be obtained directly from nature or may be synthesized artificially. [0025] For example, one such inhibitor is dihydromyricetin, which is also present in commercial compound telocapil™, and is present in concentrated extract from leaves of Myricacerifera. In one example, the composition of the present matter includes inhibitor in the range of o.oi% to 20%. I n another example, the telocapil™ is the inhibitor and the composition has the telocapil™ in the range of 0.01-20 wt% or o.i-5.owt%. I n another example, the composition comprises telocapil™ in the range of o.2-3wt%. I n another example, the inhibitor is pilisoft® LS 9760. Pilisoft® LS 9760 consist of an extract from the leaves of the Cymnema sylvestre and is rich in gymnemic acids, the triterpenoid saponins belonging to the oleanane class. Cymnema sylvestre is known as Gurmar in Ayurveda. Gymnemic acids inhibit phosphodistearase activity and this inhibition leads to an increase of the level of cAMP (cyclic adenosine monophosphate) that result in hair growth inhibition by reducing the proliferation of keratinocytes as well as reduces mitotic activity of hair follicles. The composition of the present subject matter comprises Gymnema sylvestre as pilisoft® LS9760 in the range of o.oi-2owt%. Pilisoft® LS9760 is aqua (+) pentylene glycol (+) Cymnema Sylvestre leaf extract. I n some of the embodiments the composition comprises pilisoft® LS9760 in the range of 0.1-5.0 wt%. I n other embodiments, the composition comprises pilisoft® LS9760 in the range of 0.2-3.0 wt%. In still another aspect, the present subject matter provides a composition comprises a combination of inhibitors, for example, telocapil™ 0.2-3.0 wt% and pilisoft® LS9760 0.2-3.0 wt%. [0026] In another aspect the composition comprises Narcissus tazetta bulb extract, traded as dormin (procured from Mfr IBR, traded by United Descaler Pvt Ltd. and has geographical origin of South and South Central of Israel). As per Hayflick's theory of Aging, body cells have a limited capacity to replicate and as cells advance in replication number they age. This theory was substantiated with the discovery of telomeres, the cell internal biological clock. The Narcissus tazetta bulb extract is a natural aqueous extract from dormant flower bulbs that are able to slow down the cell proliferation and capture and transfer the dormancy to hair follicles and thereby slows down hair growth. The hair growth cycles involve multiple phases from starting to grow and falling out years later such as anagen (growing phase), catagen (regression phase), telogen (resting phase), and exogen (shedding phase). Narcissus tazetta bulb extract induces the transition from anagen to catagen phase. The composition provided by present subject matter comprises dormin in the range of 0.01-20 wt%. I n some of the embodiments, dormin is present in the range of 0.1-5.0 wt%. In another embodiment, dormin is present in the range of 0.2- 3.0 wt%.

[0027] In some of the embodiments, the composition comprises papaya extract with papain enzyme. The papaya extract adds an advantage by weakening the unwanted hair follicles. The papaya extract may be present in the cosmetic composition of the subject matter in the range of 0.05- 5 wt%.

[0028] In another aspect the compositions provided by the present subject matter also offer skin lightening benefit.

[0029] As discussed earlier, while, inhibitors, such as telocapil™ (dihydromyricetin)is one of the desirable ingredients in a cosmetic composition, these also present challenges in providing a commercially viable solution. One such challenge is discoloration of the cosmetic composition. The discoloration of the cosmetic composition is not desirable because, it not only reduces aesthetic appeal of the cosmetic composition, but also, reduces the commercial value and may indicate deterioration of the composition.

[0030] The present subject matter, among others, provides a solution to this problem. The present invention provides a cosmetic composition comprising: at least one inhibitor; at least one oxidation preventing agent; and cosmetically acceptable vehicle. The oxidation preventing agent is selected from an acidifying agent, a sacrificial agent (an antioxidant), a chelator and a combination thereof. The inventor of this subject matter has observed that the discoloration of the inhibitor such as, dihydromyricetin is controlled or avoided if the pH of the composition is favourable. The present subject matter provides the inhibitors with the oxidation preventing agents. The oxidation preventing agents may be acidifying agent, antioxidants and/or chelators.

[0031] In one aspect, the oxidation preventing agent is acidifying agent. It shall become clear to a person in the art, that the acidifying agent is a hydrogen ion donor. I n some embodiments, the acidifying agent may be from a class of hydroxy or carboxylic acids. The acidifying agent is present in an amount between 0.01-25 wt%. In some of the embodiments, the acidifying agent is present in an amount between 0.1- 15 wt%. I n yet another embodiment, the acidifying agent is present in an amount between o.2-iowt%. In some examples, the acidifying agent may be glycolic acid. The acidifying agent provides an acidic environment to the inhibitor such as, dihydromyricetin and thereby preventing or delaying discoloration of the composition. In some of the embodiments the composition has a pH between 3.8 to 5.5. In other embodiments the desirable pH of the composition is between 4 to 5.

[0032] In another aspect, the oxidation preventing agent is a chelator. I n some examples, the chelator may be selected from, but not limited to, disodium ethylenediaminetetraacetate (EDTA), diethylenetriaminepentaacetic acid (DTPA), trisodium ethylenediaminedisuccinate (EDDS), gluconolactoneand a combination thereof. The chelators may be present in the composition in the range o.oi- 2.0 wt% and in some embodiments, 0.1-1.0 wt%.

[0033] In another aspect, the composition comprises sacrificial ingredients as oxidation preventing agent. Such sacrificial ingred ients (antioxidants) undergo oxidation instead of the inhibitor (e.g. dihyromyricetin) in the composition. The sacrificial agents used in the present subject matter are selected from but not limited to sodium-bisulphite, butylated hydroxytoluene (BHT), ascorbic acid and its derivatives, tocopherol and its derivatives and a combination thereof. The sacrificial ingredients may be present in the composition in the range 0.01-2.0 wt% and in some embodiments, 0.1-1.0 wt%.

[003 ] In another aspect the composition comprises a cosmetically acceptable vehicle suitable for topical application to skin and hair. Cosmetically acceptable vehicles are well known in the art and are selected based on the end use of the application. For example, the cosmetically acceptable vehicle of the present subject matter includes, but not limited to, those suitable for application to the skin. Such vehicles are well known to those of ordinary skill in the art, and can include one or more compatible liquid or solid filler diluents or vehicles which are suitable for application to the skin. The exact amount of a cosmetically acceptable vehicle will depend upon the level of any other optional ingredients that one of ordinary skill in the art would classify as distinct from the cosmetically acceptable vehicle (e.g., other active components). The compositions of the present subject matter preferably comprise from about 40% to about 99%, more preferably from about 70% to about 98%, and most preferably from about 80% to about 98%, by weight of the composition, of a cosmetically acceptable vehicle.

[0035] The cosmetically acceptable vehicle and the compositions herein can be formulated in a number of ways, including but not limited to emulsions. For example, suitable emulsions include: oil-in-water, water-in-oil, water-in-oil-in-water, oil-in-water-in- oil, oil-in-water-in-silicone emulsions or other simple aqueous formulations. Desirable compositions comprise an oil-in-water emulsion and simple aqueous formulations.

[0036] The compositions of the present invention can be formulated into a wide variety of product types, including: creams, waxes, pastes, lotions, milks, mousses, gels, oils, tonics, roll-ons, serum, concentrate, body wash, and aqueous or non-aqueous sprays. Desired compositions are formulated into lotions, serum, concentrate, roll-on, creams, gels, and aqueous sprays. These product forms may be used for a number of applications, including but not limited to, hand and body lotions, cold creams, facial moisturizers, anti-acne preparations, topical analgesics, underarm roll-on, facial serum, ingrown hair concentrate, body wash, body mist/spray and the like. Any additional components required to formulate such products vary with product type and can be routinely chosen by one skilled in the art, after reading this specification.

[0037] Other Components: The formulation also can comprise other components that may be chosen depending on the vehicle and/or the intended use of the formulation. Additional components include, but are not limited to, water soluble sunscreens (such as Eusolex 232); oil soluble sunscreens (such as octyl methoxycinnamate); and organic sunscreens (such as camphor derivatives, cinnamates, salicylates, benzophenones, triazines, PABA derivatives, diphenylacrylate derivatives, and dibenzoylmethane derivatives.); antioxidants (such as BHT); chelating agents (such as disodium EDTA); emulsion stabilizers/thickener (such as carbomer, Sepiplus 400); preservatives (such as phenoxyethanol); fragrances (such as pinene); humectants/polyols (such as glycerin, sorbitol, polyethylene glycol (PEG) , propanediol); polymers (such as PVP/Eicosene copolymer); water soluble film-formers (such as hydroxypropyl methylcellulose); oil-soluble film formers (such as hydrogenated C-9 Resin); moisturizing agents, such as cholesterol, sodium PCA; anionic polymers (such as xanthan gum); vitamins (such as tocopherol, and its derivatives, ascorbic acid and its derivatives etc.); inorganic particles (such as titanium dioxide, zinc oxide, su mica and silica) natural extracts (such as aloe-vera, saffron, licorice, papaya etc.), skin lighting actives (such as, niacinamide, arbutin, kojic acid, 4-butyl resorcinol etc.), alkaloids(kopsinol™), starch (Dryflo PC), colourants(titanium dioxide), sumica pearl, sarasilk sc86A,SFooo5Z/Sarasense CM 56, perfumeand the like.

[0038] The compositions can also encompass one or more active components, and as such can be either cosmetic or pharmaceutical compositions. Examples of useful actives include, but are not limited to, those that improve or eradicate age spots, keratoses and wrinkles, analgesics, anesthetics, anti-acne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidermatitis agents, antipruritic agents, antiemetics, antihyperkeratolytic agents, anti-dry skin agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, antiaging agents, antiwrinkle agents, sunscreen agents, antihistamine agents, depigmenting agents, wound-healing agents, vitamins, corticosteroids, tanning agents or hormones. More specific examples of useful active agents include retinoids such as retinol, and esters, acids, and aldehydes thereof; ascorbic acid, and esters and metal salts thereof, tocopherol and esters and amide derivatives thereof; milk proteins; alpha- or beta-hydroxy acids; DHEA and derivatives thereof; clotrimazole, ketoconazole, miconozole, griseofulvin, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocyline, hydroquinone, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17- valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone diproprionate, triaminolone acetonide, fluocinonide, clobetasol, proprionate, benzoyl peroxide, crotamiton, propranol, promethazine, and mixtures thereof. EXAM PLES

Example 1: Body Lotion

[0039] The subject matter is practiced in a body lotion composition as illustrated below in Table 1. Polyols could be one or more combination of glycerine, propylene glycol and 1,3 propane diol. The chelating agent, antioxidant and preservative indicated below are just one of the examples in their respective category of ingredients. The below table 1 shows, examples ιΑ and ιΒ and establishes that the composition of the present subject matter having glycolic acid as acidifying agent shows avoidance of discoloration of telocapil™ in the composition. Whereas the composition without the acidifying agent discolors.

Table 1

[00 0] To make 1 ton of finished body lotion product, required quantity of pasteurized demineralised water is charged to the main mixer. Phenoxyethanol followed by di-sodium EDTA are added and the stirring started. Then add polyol and mix for 5 minutes. Heating is started to maintain approx. 75 deg C. Titanium dioxide is added before adding the viscous Sepiplus 400. The contents are stirred well for uniform mixing. The Octylmethoxycinnamate oil is then added once the mixer content reaches 75 deg C and recirculation is started. After 5 minutes of recirculation and ensuing homogeneity, the contents of the main mixer are cooled to below 40 deg C. Then a premix of BHT and perfume is added. Followed by other ingredients one by one in the following order - niacinamide, papaya extract, and glycolic acid. Having ensured the pH to be in the range of 4 to 5, then pilisoft^® LS 9760, and telocapil™ are added. Kopsinol™is dissolved in 1,3- propane diol and after ensuring complete dissolution of kopsinol™, this premix is added to the main mixer. The contents are mixed well and then recirculated for 5 minutes to ensure homogeneity of the bulk before discharging the batch for packing. The total duration of the batch time is 1 hour. The color, odour, appearance, pH and density of the finished good are Example 2: Body Lotion

[00 1] In another example, the subject matter is practiced as a body lotion with different set of unwanted hair growth retarding ingredients (telocapil™, pilisoft® LS 9760 and dormin can be present individually and in combination of either of the other two ingredients and also all three of them together, for example telocapil™+ dormin, pilisoft LS9760 + dormin, pilisoft LS9760 alone, dormin alone) as illustrated below in Table 2.

Table 2

[00 2] In the example 2A, the entire composition is kept as is that of example IB except that pilisoft® LS 9760 is added along with telocapil™ to enhance the benefit of retarding regrowth of unwanted body hair. Example 2B is to demonstrate further enhancement of the benefit of retarding regrowth of unwanted body hair with additional ingredient dormin. The manufacturing process followed is the same as described above in example 1 and additionally pilisoft® LS 9760 and dormin as benefit ingredients are added each at 0.1-2.0 wt% along with telocapil™ at 0.5-1.5 wt%.

Example : Ingrown Hair Concentrate

[00 3] The subject matter is practiced as an ingrown hair concentrate as illustrated below in Table3.

Table 3

[00 ] To make 1 ton of ingrown hair concentrate, pasteurized hot water at 75 deg C is charged into main mixer. Di-sodium EDTA, phenoxyethanol and glycerin are added and stirred well for 5 minutes. Viscous Sepiplus 400 followed by thick paste of Sarasilk EL 63 are slowly added. Then, Octylmethoxycinnamte, Sarasense CM 56, and Sarasilk SC 86A are added in that order. The contents of the bulk are maintained at 75 deg C. the contents are recirculated for 5 minutes to ensure homogeneity of the bulk. The contents are then cooled to below 40 Deg C and a premix of BHT and perfume are added along with stirring. Sumica pearl is premixed with DM water and added to the main mixer and care is taken to ensure complete dispersion without lumps. Niacinamide is premixed with DM water and this is then added to the mixer followed by papaya extract. Glycolic acid, a low pH liquid is then carefully added to bring down the pH of the bulk contents in the range of 4 to 5, then pilisoft^® LS 9760, and telocapil™ are added. Kopsinol™ is dissolved in 1,3- propane diol and after ensuring complete dissolution of Kopsinol™, this premix is added to the main mixer. The contents are mixed well and then recirculated for 5 minutes to ensure homogeneity of the bulk before discharging the batch for packing. The total duration of the batch time is ιοο minutes. The color, odour, appearance, pH and density of the finished good are checked. Polyols could be one or more combination of glycerine, propylene glycol, 1,3, Propane diol. The chelating agent, antioxidant, and preservative indicated below are just one of the examples in their respective category of ingredients.

[00 5] The subject matter is practiced as a serum composition as illustrated below in Table 4.

Table 4

[00 6] To make 1 ton of unwanted hair regrowth retarding serum, pasteurized hot water at 75 deg C is charged into main mixer. Phenoxyethanol and glycerin are added and stirred well for 5 minutes. Thick paste of Sarasilk EL 63, Sarasense CM 56, and Sarasilk SC 86A are slowly added to the mixer in that order. The contents of the bulk are maintained at 75 deg C. The contents are recirculated for 5 minutes to ensure homogeneity of the bulk. The contents are then cooled to below 40 Deg C and a premix of BHT and perfume are added along with stirring. Sumica pearl is premixed with DM water and added to the main mixer and care is taken to ensure complete dispersion without lumps. Niacinamide is premixed with DM water and this is then added to the mixer followed by papaya extract. Glycolic acid, a low pH liquid is then carefully added to bring down the pH of the bulk contents in the range of 4 to 5, then pilisoft^® LS 9760, and telocapil™ are added. Kopsinol™ is dissolved in 1,3- propane diol and after ensuring complete dissolution of kopsinol™, this premix is added to the main mixer. The contents are mixed well and then recirculated for 5 minutes to ensure homogeneity of the bulk before discharging the batch for packing. The total duration of the batch time is 80 minutes. The color, odour, appearance, pH and density of the finished good are checked. Polyols could be one or more combination of glycerine, propylene glycol, 1,3, Propane diol. The chelating agent, antioxidant, and preservative indicated are just one of the examples in their respective category of ingredients.

Example ς: Roll-on Composition

[00 7] The subject matter is practiced as a roll-on composition as illustrated below in Table s.

Table 5

[00 8] To make 1 ton of finished Roll-on product, required quantity of pasteurized demineralised water is charged to the main mixer. Phenoxyethanol followed by disodium EDTA are added and the stirring started. Then add polyol (glycerine) and mix well for 5 minutes. Heating is started to maintain approx. 75 deg C. Titanium dioxide and dryflo PC are slowly added and stirred well to avoid lump formation. Then viscous Sepiplus 400 is slowly added and stirred well to ensure uniform mixing. The recirculation is started and after 5 minutes of recirculation and ensuing homogeneity, the contents of the main mixer are cooled to below 40 deg C. Then a premix of BHT and perfume is added when the batch contents are below 40 deg C. Followed by this, a suspension of sumica pearl in demineralized water is added and continuously stirred to achieve uniform dispersion. Then niacinamide dissolved in demineralized water is added followed by papaya extract, sodium PCA, and glycolic acid. Having ensured the pH to be in the range of 4 to 5, then pilisoft^® LS 9760, and telocapil™ are added, sensiva SC 50 is then added. Kopsinol™ is dissolved in 1,3- propane diol and after ensuring complete dissolution of kopsinol™, this premix is added to the main mixer. The contents are mixed well and then recirculated for 5 minutes to ensure homogeneity of the bulk before discharging the batch for packing. The total duration of the batch time is 105 minutes. The color, odour, appearance, pH and density of the finished good are checked.

Example 6: Body Mist Composition

[00 9] The subject matter is practiced as a body mist composition as illustrated below in Table 6.

Table 6

[0050] To make 1 ton of finished Body Mist product, required quantity of pasteurized demineralised water is charged to the main mixer and stirring done at 30 rpm for time until the temperature is brought below 40 deg C.Then 1,3- propane diol and phenoxyethanolare added and the stirring continued. The other ingredients are added in the following order one by one -glycerine and papaya extract. Care is taken to avoid lumps whenever powder material is added by stirring well. Then a premix of BHT and perfume is added. Followed by this, niacinamide, and glycolic acid are added. Having ensured the pH is in the range of 4 to 5, then pilisoft® LS 976o,telocapil™, and kopsinol™ are added to the main mixer. The contents are mixed well and then recirculated for 5 minutes to ensure homogeneity of the bulk before discharging the batch for packing. The total duration of the batch time is approx. 35 minutes. The color, odour, appearance, pH, and density of the finished good are checked.

Example 7: Hair Retard Body Wash

[0051] The subject matter is practiced as a hair retard body wash as illustrated below in Table y.

Table 7

[0052] To prepare body wash product, in one mixer unit surfactants - Sodium lauryl ether sulphate(SLEA) /Triethanolamine lauryl suphate (TEA lauryl sulphate), Cocomonoethanolamide (CMEA), Plantacare- are diluted with demineralized water with mild stirring. Chelator (EDTA) and preservative (phenoxyethanol) are then added. When the surfactants get diluted to form a homogeneous phase, Carbopol 990 is added to the paste. The paste is slowly neutralized with KOH or TEA (triethanolamine) in appropriate quantity increasing the pH to 6 - 6.2 ensuring good consistency / viscosity. After this EGDS (ethylene glycol distearate) is added with continuous stirring followed by the addition of Cocoamido propyl betaine (CAPB), glycerine, and DC 1870 (silicone derivative). To raise the viscosity, sodium chloride and polyquaternium -7 are added. To get a quality thickening Klevesol is added. When the whole mass is homogenized and is closer to room temperature, dormin, pilisoft, and papaya extract are added followed by that the fragrance.

Example 7: Assessment of anti-proliferation of human dermal papilla cells (hDPO

[0053] For the purpose of testing effect of the cosmetic composition of the present subject matter on proliferation of human dermal papilla cells, a number of experiments are performed.

[005 ] The efficacy of individual actives and their combinations on the proliferation of human dermal papilla cells (hDPC) isstudied. The actives herein refer to Telocapil™, Pilisoft™, and Dormin™. Dermal papilla cells (DP) are highly active group of mesenchymal cells derived from dermis mesenchyme and are located at the base of the hair follicles. These cells play a crucial role in hair growth cycle by inducing/regulating the hair follicle development from the epidermis and its growth. The Dermal Papilla cells were procured from PromoCell (Cat#Ci207i) and were cultured in ready to use Follicle Dermal Papilla Cell Growth medium (Cat#C2650i, Promocell).

[0055] It shall become clear to a person in the art that effect of the composition on the hair growth must studied in an environment such that the cells understudy survive during the experiment. If the cells fail to survive during the experiment, to draw a conclusion in respect effect of the composition on the hair growth is not possible. Therefore the cells under experiment must be protected as best possible from the cytotoxic effects of the composition. To ensure the same, the experiments are conducted in concentrations that are suitable for observing the effect of the composition on the cells.

[0056] The effect of actives on the proliferation of human dermal papilla (DP) cells is assessed individually as well as in combinations. The ratio of individual actives is maintained uniform in the combination study. The ratio of actives maintained as follows: Telocapil 1%: Dormin 0.2%: Pilisoft 0.2%. Cells are exposed to the actives for 72 hrs and the number of cells in each treatment well are quantitated post 72hrs. In control, cells are treated with either cell growth media or with long/ml human epidermal growth factor (hEGF). No active is added in the control. Based on luminescence intensity derived from CellTiter-Glo reagent, a linearity curve using different cell numbers was plotted to quantitate the number of cells in different treatments at the end of 72hrs incubation.

[0057] Following protocol for dermal papilla (DP) cell proliferation assay is followed for the study. First, ΐ5ομΙ of DP cells are seeded at a density of 5000 cells/well and incubated at 37^°C in 5% CO2 incubator. Second, after 24 hrs of seeding, cells are treated with 50 μΙ of appropriate actives in media. Control wells are added with either culture media or long/ml of hEGF (human epidermal growth factor). Cell culture media constitutes growth factors, amino acids, vitamins, salts and other essential nutrients to culture and grow cells. The human epidermal growth factor (hEGF) is procured from Sigma Aldrich (Cat# E9644). A stock of lmg/ml is prepared in sterile Molecular Biology grade water (Cat#W4502, Sigma Aldrich). The stock is aliquoted and stored at -20C until further use. In the DP cell proliferation assay, hEGF is used as a positive control to assess the enhanced proliferation of cells. Third, cells are further incubated for 72hrs at 37^°C in 5% CO2 incubator. Fourth, after 72hrs of incubation, 100 μΙ of CellTiter-Glo reagent was added to all the wells & incubated for 5 minutes at room temperature. Fifth, luminescence signal are captured using EnVision Multilabel plate reader. The results obtained are given shown in FIG. 1 and Table 8.

[0058] A base line is drawn and it is found (may be seen in FIG. 1) that the when the cells understudy are observed in the culture media i.e when incubated with only cell growth media (herein referred as untreated cells FIG. 1 reference UT), the growth is about 4 times the original value in about 72 hours. Whereas when the cells understudy are observed in the culture media having Epidermal Growth Factor (EGF) about long/ml the growth is about 5 times the original value in about 72 hours (FIG. 1 reference EGF). As can be seen in FIG. 1 an increase of about 400% in the number of cells when incubated with only cell growth media (herein after referred as untreated cells) as compared to initial number of cells seeded. There is further increase of 26.2% in cell proliferation when treated with hEGF as compared to untreated cells. Addition of actives decreases the proliferation of cells. Further from FIG. 1, it is clear that the combination of the actives of the present actives further enhances the antiproliferative effect as compared with the antiproliferative effect of individual actives. Legends of the FIG. 1 and Table 8 are as follows, T: Telocapil, P: Pilisoft, D: Dormin, UT: Untreated, EGF: Epidermal growth factor. The results of FIG. ι are also summarized below in Table 8.

Table 8

Example 8: Discoloration of the composition

[0059] The discoloration of the composition according to the present subject matter, having an oxidation preventing agent and without the oxidation preventing agent is studied. The compositions are observed for 12 weeks at temperature zero degree Celsius and forty five degree Celsius. At both the temperatures the composition without the oxidation preventing agent shows discoloration, whereas the composition of the present subject matter does not show any discoloration. FIG. 2 shows discoloration of the composition without oxidation preventing agent. FIG. 3 shows no discoloration of the composition according to the present subject matter. Therefore the present subject matter provides a composition which more stable and has longer shelf life.

[0060] While the subject matter described herein may be susceptible to various modifications and alternative forms. Specific embodiments have been discussed and described herein are only by way of examples. Alternate embodiments or modifications may be practiced without departing from the spirit of the subject matter. In some cases, some features may be emphasized while others are not. Further, the methods disclosed herein may be performed in manner and/or order in which the methods are explained. Alternatively, the methods may be performed in manner or order different than what is explained without departing from the spirit of the present subject matter. It should be understood that the subject matter is not intended to be limited to the particular forms disclosed. Rather, the subject matter is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the subject matter as described above.

[0061] While describing the present subject matter, some proprietary terms and generally traded names have been used. These terms and names may include some expressions that may be trademarks or copyrighted subject matter. The applicant acknowledges the ownership of the respective proprietary subject matter and states that use of such tradenames or proprietary terms are solely for the purpose of ease of explanation and not for any malicious intent.

Claims

What is claimed is:

1. A cosmetic composition comprising:

dihydromyricetin as an inhibitor;

at least one oxidation preventing agent wherein the oxidation preventing agent is selected from: an acidifying agent, an antioxidant, a chelator, and a combination thereof; and

a cosmetically acceptable vehicle.

2. The cosmetic composition of claim l, wherein the inhibitor includes any one or more of Cymnema sylvestre and Narcissus tazetta bulb extract.

3. The cosmetic composition of any one of claims 1 and 2, wherein the inhibitor is present in any amount selected from: 0.01-20 wt%, 0.1-5.0 wt% and 0.2-3 wt%.

it. The cosmetic composition of claim 1, wherein the acidifying agent is glycolic acid.

5. The cosmetic composition of claim 1, wherein the acidifying agent is present in any amount selected from: 0.01-25 wt%, o.i-io.o wt%, and 0.2 wt% - 8 wt%.

6. The cosmetic composition of claim 1, wherein the antioxidant is selected from: sodium-bisulphite, butylated hydroxytoluene (BHT), ascorbic acid and its derivatives, tocopherol and its derivatives, and a combination thereof.

7. The cosmetic composition of claim 1, wherein the antioxidant is present in any amount selected from: o.oi wt% to 2 wt%, and 0.1 wt% to 1 wt%.

8. The cosmetic composition of claim 1, wherein the chelator is selected from: disodium ethylenediaminetetraacetate (EDTA), diethylenetriaminepentaacetic acid

(DTPA), trisodium ethylenediaminedisuccinate (EDDS), and a combination thereof.

9. The cosmetic composition of claim 1, wherein the chelator is present in any amount selected from: o.oi - 2.0 wt% and 0.1- 1.0 wt%.

10. The cosmetic composition of claim 1, wherein the composition further comprises a polyol selected from 1,3-propane diol, propylene glycol, glycerol, sorbitol, and polyethylene glycol.

11. The cosmetic composition of claim 10, wherein the polyol is present in any amount selected from: 0.1- 30 wt%, 0.2- 20 wt% and 0.5- 16 wt%.

12. The cosmetic composition of claim i, wherein the composition has a pH value in any one of the range of: 3.8-5.5, 4.0-5.5 and 4.0- 5.0.

13. A cosmetic composition comprising dihydromyricetin in an amount of o.oi- 25wt %; Cymnema sylvestre in an amount of 0.01-25 wt %; glycolic acid in an amount of o.oi-2owt %; and cosmetically acceptable vehicle.

14. A cosmetic composition comprising: a combination of Cymnema sylvestre and Narcissus tazetta bulb extract as inhibitor and a cosmetically acceptable vehicle.